新型血清和胆汁蛋白标志物预测原发性硬化性胆管炎疾病严重程度和预后
研究利用63种蛋白的微珠阵列检测挪威和芬兰的原发性硬化性胆管炎(PSC)患者胆汁及血清样本,发现胆汁中14种蛋白在PSC与对照间有差异,24种蛋白与胆管造影改变严重程度相关;血清IL-8可区分无移植生存期,但ELFTM和Mayo风险评分预测更强。
要点
- 胆汁中IL-8、MMP9/LCN2复合物、S100A8/9、S100A12和TPH2与PSC诊断及胆管造影改变分级相关。
- 血清IL-8按三分位分层可区分无移植生存期,且在多变量分析中独立于年龄和病程。
- ELFTM和Mayo风险评分对无移植生存期的预测强于血清IL-8。
核心结论
- 基于胆汁蛋白检测,研究识别出新型胆汁和血清生物标志物可作为PSC严重程度和预后的指标。
研究设计与样本
- 研究采用微珠阵列靶向63种蛋白,检测挪威ERCP胆汁发现面板(55例PSC,20例疾病对照)和芬兰验证面板(34例PSC,10例疾病对照)。
- 在挪威两个PSC血清队列(n=167[1992-2006]和n=138[2008-2012])、炎症性肠病(n=96)和健康对照(n=100)中检测选定蛋白。
主要发现
- 胆汁发现面板中14种蛋白在PSC患者与对照间水平不同(p<0.05),均在验证面板中确认。
- 胆汁发现面板中24种蛋白在轻度与重度胆管造影改变(改良Amsterdam标准)的PSC患者间有显著差异(p<0.05),验证面板中18种蛋白重复验证。
- 胆汁IL-8、MMP9/LCN2复合物、S100A8/9、S100A12和TPH2与PSC诊断及胆管造影改变分级均相关。
- 按血清IL-8三分位分层对无移植生存期有极好区分度,而MMP9/LCN2和S100A12无此区分度,在血清发现和验证队列中均如此。
- 血清IL-8在多变量分析中与无移植生存期相关,独立于年龄和病程,表明对PSC进展有独立影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. We aimed to identify novel protein biomarkers of disease severity and prognosis in primary sclerosing cholangitis (PSC). METHODS: Using a bead-based array targeting 63 proteins, we profiled a derivation panel of Norwegian endoscopic retrograde cholangiography bile samples (55 PSC, 20 disease controls) and a Finnish validation panel (34 PSC, 10 disease controls). Selected identified proteins were measured in serum from two Norwegian PSC cohorts (n=167 [1992-2006] and n=138 [2008-2012]), inflammatory bowel disease (n=96) and healthy controls (n=100). RESULTS: In the bile derivation panel, the levels of 14 proteins were different between PSC patients and controls (p<0.05); all were confirmed in the validation panel. Twenty-four proteins in the bile derivation panel were significantly (p<0.05) different between PSC patients with mild compared to severe cholangiographic changes (modified Amsterdam criteria); this was replicated for 18 proteins in the validation panel. Interleukin (IL)-8, matrix metallopeptidase (MMP)9/lipocalin (LCN)2-complex, S100A8/9, S100A12 and tryptophan hydroxylase (TPH)2 in the bile were associated with both a PSC diagnosis and grade of cholangiographic changes. Stratifying PSC patients according to tertiles of serum IL-8, but not MMP9/LCN2 and S100A12, provided excellent discrimination for transplant-free survival both in the serum derivation and validation cohort. Furthermore, IL-8 was associated with transplant-free survival in multivariable analyses in both serum panels independently of age and disease duration, indicating an independent influence on PSC progression. However, the Enhanced Liver Fibrosis (ELF®) test and Mayo risk score proved to be stronger predictors of transplant-free survival. CONCLUSIONS: Based on assaying of biliary proteins, we have identified novel biliary and serum biomarkers as indicators of severity and prognosis in PSC. LAY SUMMARY: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. We have identified inflammatory proteins including calprotectin and IL-8 as important indicators of disease severity and prognosis in bile and serum from patients with primary sclerosing cholangitis.
引用
- Vesterhus M, Holm A, Hov JR, et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol. 2017. PMID: 28161472. doi:10.1016/j.jhep.2017.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。